Abstract
MicroRNAs are important regulators of gene expression in normal development and disease. miR-9 is overexpressed in several cancer forms, including brain tumours, hepatocellular carcinomas, breast cancer and Hodgkin lymphoma (HL). Here we demonstrated a relevance for miR-9 in HL pathogenesis and identified two new targets Dicer1 and HuR. HL is characterized by a massive infiltration of immune cells and fibroblasts in the tumour, whereas malignant cells represent only 1% of the tumour mass. These infiltrates provide important survival and growth signals to the tumour cells, and several lines of evidence indicate that they are essential for the persistence of HL. We show that inhibition of miR-9 leads to derepression of DICER and HuR, which in turn results in a decrease in cytokine production by HL cells followed by an impaired ability to attract normal inflammatory cells. Finally, inhibition of miR-9 by a systemically delivered antimiR-9 in a xenograft model of HL increases the protein levels of HuR and DICER1 and results in decreased tumour outgrowth, confirming that miR-9 actively participates in HL pathogenesis and points to miR-9 as a potential therapeutic target.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Accession codes
References
Schetter AJ, Nguyen GH, Bowman ED, Mathe EA, Yuen ST, Hawkes JE et al. Association of inflammation-related and microRNA gene expression with cancer-specific mortality of colon adenocarcinoma. Clin Cancer Res 2009; 15: 5878–5887.
Grivennikov SI, Greten FR, Karin M . Immunity, inflammation, and cancer. Cell Mol Life Sci [Review] 2010; 140: 883–899.
Kuppers R . The biology of Hodgkin's lymphoma. Nat Rev Cancer 2009; 9: 15–27.
Brauninger A, Schmitz R, Bechtel D, Renne C, Hansmann ML, Kuppers R . Molecular biology of Hodgkin's and Reed/Sternberg cells in Hodgkin's lymphoma. Int J Cancer 2006; 118: 1853–1861.
Krol J, Loedige I, Filipowicz W . The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet 2010; 11: 597–610.
Esquela-Kerscher A, Slack FJ . Oncomirs—microRNAs with a role in cancer. Nat Rev Cancer 2006; 6: 259–269.
Ma L, Young J, Prabhala H, Pan E, Mestdagh P, Muth D et al. miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol 2010; 12: 247–256.
Bazzoni F, Rossato M, Fabbri M, Gaudiosi D, Mirolo M, Mori L et al. Induction and regulatory function of miR-9 in human monocytes and neutrophils exposed to proinflammatory signals. Proc Natl Acad Sci USA 2009; 106: 5282–5287.
Lawrie CH, Saunders NJ, Soneji S, Palazzo S, Dunlop HM, Cooper CD et al. MicroRNA expression in lymphocyte development and malignancy. Leukemia 2008; 22: 1440–1446.
Van Vlierberghe P, De Weer A, Mestdagh P, Feys T, De Preter K, De Paepe P et al. Comparison of miRNA profiles of microdissected Hodgkin/Reed-Sternberg cells and Hodgkin cell lines versus CD77+ B-cells reveals a distinct subset of differentially expressed miRNAs. Br J Haematol 2009; 147: 686–690.
Navarro A, Gaya A, Martinez A, Urbano-Ispizua A, Pons A, Balague O et al. MicroRNA expression profiling in classic Hodgkin lymphoma. Blood 2008; 111: 2825–2832.
Nie K, Gomez M, Landgraf P, Garcia JF, Liu Y, Tan LH et al. MicroRNA-mediated down-regulation of PRDM1/Blimp-1 in Hodgkin/Reed-Sternberg cells: a potential pathogenetic lesion in Hodgkin lymphomas. Am J Pathol 2008; 173: 242–252.
Lambertz I, Nittner D, Mestdagh P, Denecker G, Vandesompele J, Dyer MA et al. Monoallelic but not biallelic loss of Dicer1 promotes tumorigenesis in vivo Dicer1 is a haploinsufficient tumor suppressor. Cell Death Differ 2010; 17: 8.
Kumar MS, Pester RE, Chen CY, Lane K, Chin C, Lu J et al. Dicer1 functions as a haploinsufficient tumor suppressor. Genes Dev 2009; 23: 4.
Khabar KS . Post-transcriptional control during chronic inflammation and cancer: a focus on AU-rich elements. Cell Mol Life Sci 2010; 67: 2937–2955.
Anderson P . Post-transcriptional control of cytokine production. Nat Immunol 2008; 9: 353–359.
Obad S, dos Santos CO, Petri A, Heidenblad M, Broom O, Ruse C et al. Silencing of microRNA families by seed-targeting tiny LNAs. Nat Genet 2011; 43: 371–378.
Lopez-Rodriguez C, Aramburu J, Jin L, Rakeman AS, Michino M, Rao A . Bridging the NFAT and NF-kappaB families: NFAT5 dimerization regulates cytokine gene transcription in response to osmotic stress. Immunity 2001; 15: 47–58.
Medzhitov R, Horng T . Transcriptional control of the inflammatory response. Nat Rev Immunol 2009; 9: 692–703.
Ørom UA NF, Lund AH . MicroRNA-10a binds the 5′UTR of ribosomal protein mRNAs and enhances their translation. Mol Cell 2008; 30: 11.
Christoffersen NR, Shalgi R, Frankel LB, Leucci E, Lees M, Klausen M et al. p53-independent upregulation of miR-34a during oncogene-induced senescence represses MYC. Cell Death Differ 2010; 17: 236–245.
Wynendaele J, Bohnke A, Leucci E, Nielsen SJ, Lambertz I, Hammer S et al. An illegitimate microRNA target site within the 3′ UTR of MDM4 affects ovarian cancer progression and chemosensitivity. Cancer Res 2010; 70: 9641–9649.
Lopez de Silanes I, Zhan M, Lal A, Yang X, Gorospe M . Identification of a target RNA motif for RNA-binding protein HuR. Proc Natl Acad Sci USA 2004; 101: 2987–2992.
Marstrand TT, Frellsen J, Moltke I, Thiim M, Valen E, Retelska D et al. Asap: a framework for over-representation statistics for transcription factor binding sites. PLoS One 2008; 3: e1623.
Mukherjee N, Corcoran DL, Nusbaum JD, Reid DW, Georgiev S, Hafner M et al. Integrative regulatory mapping indicates that the RNA-binding protein HuR couples pre-mRNA processing and mRNA stability. Mol Cell 2011; 43: 327–339.
Lebedeva S, Jens M, Theil K, Schwanhausser B, Selbach M, Landthaler M et al. Transcriptome-wide analysis of regulatory interactions of the RNA-binding protein HuR. Mol Cell 2011; 43: 340–352.
Dewan MZ WM, Ahmed S, Terashima K, Horiuchi S, Sata T, Honda M et al. Hodgkin's lymphoma cells are efficiently engrafted and tumor marker CD30 is expressed with constitutive nuclear factor-kappaB activity in unconditioned NOD/SCID/gammac(null) mice. Cancer Sci 2005; 96: 7.
Ventura A, Jacks T . MicroRNAs and cancer: short RNAs go a long way. Cell 2009; 136: 586–591.
Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435: 834–838.
Kumar MS, Lu J, Mercer KL, Golub TR, Jacks T . Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet 2007; 39: 673–677.
Martello G, Rosato A, Ferrari F, Manfrin A, Cordenonsi M, Dupont S et al. A MicroRNA targeting dicer for metastasis control. Cell 2010; 141: 1195–1207.
Dean JL, Sully G, Clark AR, Saklatvala J . The involvement of AU-rich element-binding proteins in p38 mitogen-activated protein kinase pathway-mediated mRNA stabilisation. Cell Signal 2004; 16: 1113–1121.
Lu JY, Schneider RJ . Tissue distribution of AU-rich mRNA-binding proteins involved in regulation of mRNA decay. J Biol Chem 2004; 279: 12974–12979.
Kawai T, Lal A, Yang X, Galban S, Mazan-Mamczarz K, Gorospe M . Translational control of cytochrome c by RNA-binding proteins TIA-1 and HuR. Mol Cell Biol 2006; 26: 3295–3307.
Linker K, Pautz A, Fechir M, Hubrich T, Greeve J, Kleinert H . Involvement of KSRP in the post-transcriptional regulation of human iNOS expression-complex interplay of KSRP with TTP and HuR. Nucleic Acids Res 2005; 33: 4813–4827.
Katsanou V PO, Milatos S, Blackshear PJ, Anderson P, Kollias G, Kontoyiannis DL . HuR as a negative posttranscriptional modulator in inflammation. Mol Cell 2005; 19: 12.
Aldinucci D, Lorenzon D, Cattaruzza L, Pinto A, Gloghini A, Carbone A et al. Expression of CCR5 receptors on Reed-Sternberg cells and Hodgkin lymphoma cell lines: involvement of CCL5/Rantes in tumor cell growth and microenvironmental interactions. Int J Cancer 2008; 122: 769–776.
Skinnider BF, Mak TW . The role of cytokines in classical Hodgkin lymphoma. Blood 2002; 99: 4283–4297.
Khan G . Epstein-Barr virus, cytokines, and inflammation: a cocktail for the pathogenesis of Hodgkin's lymphoma? Exp Hematol 2006; 34: 399–406.
Kota SK, Balasubramanian S . Cancer therapy via modulation of micro RNA levels: a promising future. Drug Discov Today 2010; 15: 733–740.
Ma L, Reinhardt F, Pan E, Soutschek J, Bhat B, Marcusson EG et al. Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat Biotechnol 2010; 28: 341–347.
Stein CA, Hansen JB, Lai J, Wu S, Voskresenskiy A, Hog A et al. Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents. Nucleic Acids Res 2010; 38: e3.
Gentleman R, Carey V, Huber W, Irizarry R, Dudoit S . Bioinformatics and Computational Biology Solutions Using R and Bioconductor [Book] 2005; 473.
Huber W, von Heydebreck A, Sultmann H, Poustka A, Vingron M . Variance stabilization applied to microarray data calibration and to the quantification of differential expression. Bioinformatics 2002; 18 (Suppl 1): S96–S104.
G S . Limma: linear models for microarray data. In: Gentleman RCV, Dudoit S, Irizarry R, Huber W (eds). Bioinformatics and Computational Biology, Solutions using R and Bioconductor [Chapter] 2005; 23.
Acknowledgements
This work was supported by The Danish National Advanced Technology Foundation, The EC FP7 ONCOMIRS consortium (Grant agreement number 201102: this publication reflects only authors' views;the commission is not liable for any use that may be made of the information herein), The Novo Nordisk Foundation, The Lundbeck Foundation, The Danish Cancer Society and the Danish National Research Foundation. Dr Bellan's and Professor Leoncini's work is supported by the Monte dei Paschi di Siena Foundation. Dr Leucci is supported by a grant from the Danish Medical Research Council.
Author contributions: EL and AHL designed the overall study. SO and SK designed and provided the tiny anti-miR-LNAs. LHG performed all the bioinformatic analyses. LL and CB performed the analysis on NOG MICE. KTJ coordinated the mouse experiments; AZ and EL performed all the experiments. EL and AHL wrote the paper.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
Dr Obad and Professor Kauppinen are employees of Santaris Pharma. The other authors declare no conflict of interest.
Additional information
Supplementary Information accompanies the paper on the Oncogene website
Supplementary information
Rights and permissions
About this article
Cite this article
Leucci, E., Zriwil, A., Gregersen, L. et al. Inhibition of miR-9 de-represses HuR and DICER1 and impairs Hodgkin lymphoma tumour outgrowth in vivo. Oncogene 31, 5081–5089 (2012). https://doi.org/10.1038/onc.2012.15
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2012.15
Keywords
This article is cited by
-
MicroRNA signature in classical Hodgkin lymphoma
Journal of Applied Genetics (2021)
-
MicroRNAs and their role in environmental chemical carcinogenesis
Environmental Geochemistry and Health (2019)
-
miR-9-5p, miR-124-3p, and miR-132-3p regulate BCL2L11 in tuberous sclerosis complex angiomyolipoma
Laboratory Investigation (2018)
-
Protective role for miR-9-5p in the fibrogenic transformation of human dermal fibroblasts
Fibrogenesis & Tissue Repair (2016)
-
Krüppel-like factor 17, a novel tumor suppressor: its low expression is involved in cancer metastasis
Tumor Biology (2016)